

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

Craig A. Coburn, et al.

Serial No.:

10/593,808

Case No.: 21664Y

US Nat'l Filing Date:

September 20, 2006

Int'l Appl'n No.

PCT/US2005/010224

Int'l Filing Date:

March 25, 2005

For:

2-AMINOTHIAZOLE COMPOUNDS USEFUL AS ASPARTYL

PROTEASE INHIBITORS

Mail Stop PCT Commissioner for Patents P.O. BOX 1450 Alexandria, VA 22313-1450

## INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR § 1.97

Sir:

In compliance with 37 CFR § 1.97, Applicants and other individuals associated with the filing or prosecution of this application wish to bring to the attention of the Examiner the patents, publications, and other information of which they are aware, listed on the attached form PTO-1449, which they believe may be relevant to the examination of this application or may be material to patentability and in respect of which there may be a duty to disclose in accordance with 37 CFR § 1.56. Applicants respectfully request that the Examiner initial the form PTO-1449 after reviewing the pertinence of each reference.

This Information Disclosure Statement is not an admission that any patent, publication, or other information referred to herein is "prior art" for this invention.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on the date appearing below.

MERCK & CO., INC.

Regiolds Date 617/08

U.S. Serial No..: 10/593,808

Case No.:

21664Y

Page

2

In accordance with 37 CFR § 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b). In accordance with 37 CFR § 1.97(g), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made.

References A- G on the accompanying PTO 1440 form were cited in the Supplemental Search Report of the European Patent Office for the European counterpart of this application. A copy of the Supplemental Search Report is enclosed with the Information Disclosure Statement.

Pursuant to 37 C.F.R. §1.97(b) the Information Disclosure Statement is being filed before the mailing of a first office action on the merits Accordingly, it is believed that no fee is due.

Any additional fees required in connection with this submission may be taken from Merck Deposit Account No. 13-2755.

Respectfully submitted,

John C. Todaro, Reg. No. 36,036 Attorney for Applicant

MERCK & CO., Inc. P.O. Box 2000 Rahway, New Jersey 07065-0907 (732) 594-0125

6/17/2w8 Date: